This study identifies BAG2 as a key player in DNAJ-PKAc-mediated chemotherapeutic resistance in fibrolamellar carcinoma by linking it to Hsp70 and Bcl-2.

bioRxiv · Jun 28, 2023Cancer Biology

Oncogenic PKA signaling stabilizes MYC oncoproteins via an aurora kinase A-dependent mechanism

G. K. L. Chan, S. Maisel, Y. C. Hwang, R. R. B. Wolber, P. Vu, K. C. Patra, M. Bouhaddou, H. L. Kenerson, R. S. Yeung, D. L. Swaney, N. J. Krogan, R. E. Turnham, J. D. Scott, K. J. Riehle, N. Bardeesy, J. D. Gordan

This study identifies two PKA-driven oncogenic mechanisms, showing AURKA stabilizes MYC oncoproteins through a PIM2-mediated feedback loop, and suggests CD-532 as a potential therapeutic target.

bioRxiv · Apr 16, 2021Cancer Biology

A Microfluidic Platform for Functional Testing of Cancer Drugs on Intact Tumor Slices

A. D. Rodriguez, L. F. Horowitz, K. Castro, H. Kenerson, N. Bhattacharjee, G. Gandhe, A. Raman, R. J. Monnat, R. S. Yeung, R. C. Rostomily, A. Folch

This paper develops a microfluidic platform for testing cancer drugs on intact tumor slices to improve drug response assessment in precision oncology.

bioRxiv · Mar 2, 2020Bioengineering

Kinome-centric pharmacoproteomics identifies signaling pathways underlying cellular responses to targeted cancer drugs

M. Golkowski, H.-T. Lau, M. Chan, H. Kenerson, V. N. Vidadala, A. Shoemaker, D. J. Maly, R. S. Yeung, T. S. Gujral, S.-E. Ong

The paper develops a kinome-centric pharmacoproteomics platform to identify signaling pathways and biomarkers predicting cancer drug responses and resistance in hepatocellular carcinoma.

bioRxiv · Nov 20, 2019Cancer Biology